Despite the relatively high prevalence of hypertrophic cardiomyopathy (HCM), reported to be as high as 1 in 200 individuals, most individuals are undiagnosed and untreated. The pathophysiology of HCM is complex and consists of multiple interrelated abnormalities. In order to move the needle from an often-fatal condition to a treatable chronic condition, clinicians must be able to identify patients, understand the challenges of diagnosis, and implement new and emerging treatment options for their patients.
The categories are...Join us for a unique and interactive educational symposium on HCM. In this jeopardy-style symposium, align yourself with one of our expert panelists and let your knowledge of HCM guide your team to victory!
Welcome and Introductions - Audience Team Selection
Round 1 - The categories are:
- Epidemiology
- Pathophysiology
- Diagnosis
- Risk stratification
- Exercise capacity
Round 2 - The categories are:
- Pharmacotherapy
- Emerging strategies
- Devices
- Invasive management
- Advanced therapies in HF
- Gene therapy
Final Round!
- Patient case challenges
Panel Discussion and Q&A
GOAL STATEMENT
The goal of this activity is for learners to be better able to recognize the clinical and patient burden of HCM, identify and manage HCM, and evaluate the rationale and latest clinical data for novel disease-modifying treatments and implications for improved patient care.
LEARNING OBJECTIVES
Upon completion of this activity, participants will: Have increased knowledge regarding the[LIST][ITEM]Unmet needs in the treatment of HCM[ITEM]Guideline recommendations for the management of HCM[ITEM]Latest clinical evidence evaluating cardiac myosin inhibition for the treatment of HCM[/LIST]Have greater competence related to[LIST][ITEM]The selection of the most appropriate treatment for patients with HCM in accordance with the latest evidence and guidelines[/LIST]Demonstrate greater confidence in their ability to[LIST][ITEM]Work as part of an interprofessional team to identify patients who would benefit from cardiac myosin inhibition therapy[/LIST]
ACCREDITATION STATEMENT
In support of improving patient care, Medscape, LLC is jointly accredited with commendation by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. [JALOGO] [MEDSCAPE]
[bold]For Physicians[/bold] Medscape, LLC designates this live activity for a maximum of 1.5 [italic][bold]AMA PRA Category 1 Credits[/bold][/italic]™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. [bold]For Nurses[/bold] Awarded 1.50 contact hour(s) of nursing continuing professional development for RNs and APNs. [bold]For Pharmacists[/bold] Medscape designates this continuing education activity for 1.50 contact hour(s) (0.150 CEUs) (Universal Activity Number: JA0007105-0000-23-197-L01-P).
Huntington Convention Center
Room 1
300 Lakeside Ave E
Cleveland, Ohio, 44113
United States
This Satellite Session is not part of the scientific program as planned by the HFSA Program Committee. The program topic, learning objectives, and faculty have been reviewed and approved by the ASM Program Review Committee for a satellite program at ASM 2023.
Supported by an independent educational grant from [bold]Cytokinetics[/bold].
Organized by